The gene editing technology was used to carry out target knockout of zc3h12b gene of Oryzias latipes, establishing Oryzias latipes missing Zc3h12b protein product. The established Oryzias latipes all show different degrees of liver lesions such as hepatobiliary duct hyperplasia and fusion, hepatocyte steatosis, and fibrosis. With increase of months, significant fatty liver appears with local cyst necrosis, obvious lymphocyte infiltration in liver sinusoids and abnormal increase in number of macrophages. Human tumor markers cytokeratin 19 (CK19), smooth muscle actin (SMA) and glypican-3 (GPC3) positive cells are also detected. It is suggested that ZC3H12B can be used as a treatment target and a biomarker for biliary cystadenoma (BCA), biliary cystadenocarcinoma (BCAC), or fatty liver or liver cancer related to BCA or BCAC. The zc3h12b missing Oryzias latipes can be used as an animal model in researches on pathological processes of BCA, BCAC, or fatty liver or liver cancer related to BCA or BCAC.

Disclosed herein are methods and systems for determining whether a cell is resistant to one or more drugs. Also, disclosed herein are methods and systems for monitoring the treatment of a cancer patient to determine whether the cancerous cells being treated are resistant to the treatment. Further, disclosed herein are methods and systems for predicting the responsiveness of a cell to a drug. Also, disclosed herein are methods and systems to determine the rate of the efficacy of a chemotherapeutic drug on a cancerous, neoplastic or damaged cells

Systems and methods are provided for evaluating the quality of a semen sample at a mobile device. An assembly includes an optical assembly with at least one lens and a housing configured to engage with the mobile device such that an axis of the optical assembly is substantially aligned with a camera of the mobile device. The optical assembly is contained within the housing. A microfluidic chip includes a reservoir to hold the semen sample. The microfluidic chip engages with the housing such that the reservoir is aligned with the axis of the optical assembly.

A method for decomposing dermatan sulfate and heparan sulfate contained in a sample into a disaccharide, respectively, wherein the dermatan sulfate is decomposed into a disaccharide in which a uronic acid and an amino sugar are joined with an α-1,3 bond, and the heparan sulfate is decomposed into the disaccharide in which the uronic acid and the amino sugar are joined with the α-1,4 bond, and wherein, the dermatane sulfate is decomposed by heating in hydrogen chloride methanol solution containing 2,2-dimethoxypropane, at a temperature of 60 to 80° C., and for 20 to 100 minutes, and the heparan sulfate is decomposed by heating in hydrogen chloride methanol solution containing 2,2-dimethoxypropane, for 80 to 180 minutes, and at a temperature of 65 to 85° C.

An object of the present invention is to find a ligand for a DCIR and to search for an agonist and an antagonist for the DCIR.

Specifically, disclosed are: a dendritic cell immunoreceptor agonist containing keratan sulfate-II (KS-II) as an active ingredient; an antibody against dendritic cell immunoreceptor, having a keratan sulfate-II-like dendritic cell immunoreceptor agonism; and an antibody against a dendritic cell immunoreceptor, having a keratan sulfate-II inhibitory dendritic cell immunoreceptor antagonism.

This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.

The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Disclosed is a method for measuring a clotting time, including the steps of: (A) mixing a blood sample, an activator, a phospholipid, and a nickel ion-forming compound to obtain a specimen; and (B) mixing the specimen obtained in step (A) with a calcium salt to prepare a measurement specimen and measuring the clotting time of the measurement specimen.

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.